3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Carboplatin
15
Etoposide
13
atezolizumab
9
Topotecan
8
durvalumab
7
Specimen Handling
7
PM 01183
6
Cisplatin
5
pembrolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Injections
3
Biopsy
3
berzosertib
2
Nivolumab
2
Fulvestrant
2
Drug Therapy
2
AMG 757
2
tremelimumab
1
trastuzumab deruxtecan
1
toripalimab
1
tazemetostat
1
palbociclib
1
olaparib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
cabozantinib
1
budigalimab
1
arginine decarboxylase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
sacituzumab govitecan
×
30 days
×
Clear all
No trials found.